CDK4/6抑制剂联合内分泌治疗晚期乳腺癌

doi:10.11904/j.issn.1002-3070.2021.03.018

Abstract

Abstract: Endocrine therapy is the main treatment method for patients with hormone receptor positive(HR+)advanced breast cancer due to its remarkable curative effect and safety.In recent years,the field of endocrinology has developed rapidly.How to delay or reverse endocrine resistance and new endocrine therapy drugs have become the focus of clinical research.Studies have found that endocrine therapy resistance may be related to the CDK-RB-E2F pathway.It has been found that endocrine therapy resistance may be related to the CDK-RB-E2F pathway.Cyclin-dependent kinase(CDK)4/6 inhibitors targeting this pathway can significantly delay endocrine resistance in patients with HR+ advanced breast cancer.The combined use of CDK4/6 inhibitors and endocrine drugs can improve the objective response rate of patients with HR+ advanced breast cancer,and can significantly improve progression-free survival(PFS).This article reviews the mechanism of action,drug effectiveness and safety of CDK4/6 inhibitors,and related clinical trials.

Key words: Advanced breast cancer, CDK4/6 inhibitor, Endocrine therapy, Cell cycle

CLC Number:

R737.9

TI Qian, ZHANG Qingyuan. Research progress of CDK4/6 inhibitors combined with endocrine therapy for advanced breast cancer[J]. Journal of Practical Oncology, 2021, 35(3): 287-290.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.03.018

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I3/287

References

1 桂欣钰.CDK4/6抑制剂在激素受体阳性进展期乳腺癌治疗中的研究进展[J].中国肿瘤临床,2020,47(6):314-317.
2 Choo JR,Lee SC.CDK4-6 inhibitors in breast cancer:current status and future development[J].Expert Opin Drug Metab Toxicol,2018,14(11):1123-1138.
3 刘尔钰,杨昊,梁国华,等.CDK4/6 抑制剂联合 mTOR抑制剂在乳腺癌中的作用机制[J].实用肿瘤学杂志,2019,33(5):476-480.
4 Sini V,Cinieri S,Conte P,et al.Eendocrine therapy in post-menopausal women with metastatic breast cancer:from literature and guidelines to clinical practice[J].Crit Rev Oncol Hematol,2016,100:57-68.
5 李田宏,郭放谢晓东.2018年ASCO年会CDK4/6抑制剂联合内分泌治疗晚期乳腺癌最新进展解读[J].中外内分泌外科杂志,2019,13(2):159-161.
6 石磊,陈占红,王晓稼.2018年美国ASCO年会晚期乳腺癌内分泌治疗进展[J].中国肿瘤临床,2018,45(18);919-921.
7 周雅洁.CDK4/6抑制剂帕博西尼的研究进展[J].同济大学学报(医学版),2020,41(2):259-263.
8 De Luca A,Maiello MR,D′Alessio A,et al.Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer[J].Expert Opin Drug Metab Toxicol,2018,14(9):891-900.
9 Finn RS,Boer K,Bondarenko I,et al.Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer(PALOMA-1,TRIO-18)[J].Breast Cancer Res Treat,2020,183(2):419-428.
10 Rugo HS,Finn RS,Diéras V,et al.Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor2-negative advanced breast cancer with extended follow-up[J].Breast Cancer Res Treat,2019,174(3):719-729.
11 Cristofanilli M,DeMichele A,Giorgetti C,et al.Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3[J].Eur J Cancer,2018,104:21-31.
12 Masuda N,Inoue K,Nakamura R,et al.Palbociclib in combination with fulvestrant in patients with hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer:PALOMA-3 subgroup analysis of Japanese patients[J].Int J Clin Oncol,2019,24(3):262-273.
13 Rascon K,Flajc G,De Angelis C,et al.Ribociclib in HR+/HER2-advanced or metastatic breast cancer patients[J].Ann Pharmacother,2019,53(5):501-509.
14 Hortobagyi GN,Stemmer SM,Burris HA,et al.Updated results from MONALEESA-2,a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive,HER2-negative advanced breast cancer[J].Ann Oncol,2018,29(7):1541-1547.
15 Tripathy D,Im SA,Colleoni M,et al.Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive,advanced breast cancer(MONALEESA-7):a randomised phase 3 trial[J].Lancet Oncol,2018,19(7):904-915.
16 Slamon DJ,Neven P,Chia S,et al.Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer:MONALEESA-3[J].J Clin Oncol,2018,26(24):2465-2472.
17 Kotake T,Toi M.Abemaciclib for the treatment of breast cancer[J].Expert Opin Pharmacother,2018,19(5):517-524.
18 Dickler MN,Tolaney SM,Rugo HS,et al.MONARCH 1,A phase II study of abemaciclib,a CDK4 and CDK6 inhibitor,as a single agent,in patients with refractory HR(+)/HER2(-)metastatic breast cancer[J].Clin Cancer Res,2017,23(17):5218-5224.
19 Sledge GW Jr,Toi M,Neven P,et al.The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive,ERBB2-negative breast cancer that progressed on,endocrine therapy-MONARCH2:a randomized clinical trial[J].JAMA Oncol,2019,6(1):116-24.
20 Johnston S,Martin M,Di Leo A,et al.MONARCH 3 final PFS:a randomized study of abemaciclib as initial therapy for advanced breast cancer[J].NPJ Breast Cancer,2019,5:5.
21 Goetz MP,Toi M,Campone M,et al.MONARCH 3:abemaciclib as initial therapy for advanced breast cancer[J].J Clin Oncol,2017,35(32):3638-3646.

[1]	LIU Eryu, YANG Hao, LIANG Guohua, ZHAO Yanfang, ZHAO Wenhui. Action for CDK4/6 inhibitors combined with mTOR inhibitors in breast cancer and its mechanism [J]. Journal of Practical Oncology, 2019, 33(5): 476-480.
[2]	HOU Congfang, DA Lintai. Research progress of RbAP48 and malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 445-449.
[3]	LIN Rongjie, YIN Hang, ZHOU Yunfeng. Effect of ON123300 on ER+ human breast cancer MCF-7 cells and its mechanism [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 193-197.
[4]	SHI Lei,XU Peiquan. The present situation of endocrine therapy in premenopausal patients with positive hormone receptor breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 170-174.
[5]	DAI Meng, LI Rui, LIU Guiting, LIANG Jinlong, FENG Jinfa, XU Shanyong. The feasibility analysis of breast conserving surgery after neoadjuvant chemotherapy in the treatment with advanced breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 109-113.
[6]	LIU Yuexin,ZHOU Qi,YAN Jinyin,HU Wanning. The research progress on antitumor function of allicin [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 557-560.
[7]	YAO Zhifeng, YAO Jianxin, XU Guoping, LIU Yongbiao. Radiosensitization of Cetuximab on pulmonary adenocarcinoma A549 cells line [J]. PRACTICAL ONCOLOGY JOURNAL, 2013, 27(1): 11-16.
[8]	LUAN Tian,TONG Lei,XU Wei,ZHONG Zhaohua. MiR-122 stimulates the apoptosis of hepatoma cell Huh-7 [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(5): 428-431.
[9]	LUO Min,GU Linhui,FENG Jianguo,LIN Nengming,SU Dan,XU Haiyan,XU Yasi. The biological effect on PolyphyllinsⅠto human ovarian cancer cells line in vitro [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(4): 293-297.
[10]	MO Xueli,WANG Delin,CAO Yujuan,DU Fang,CAO Feng,SUN Jianhua,LIU Chengwei,HAO Longying. Concurrent chemoradiotherapy with weekly Paclitaxol in advanced breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2011, 25(5): 437-438.
[11]	XU Xiaoying, LI Xiurong, LI Na, LEI Hongwei, SU Xu, LI Guoquan. Influence of survivin gene expression inhibition with siRNA on the cell cycle of HeLa cell line [J]. PRACTICAL ONCOLOGY JOURNAL, 2010, 24(4): 368-372.
[12]	SUN Xiyuan, SUN Jianli. The First Effect of Yi Qi Yang Yin Fang on Reversing Multidrug Resistsnce of the Human Lung Adenocarcinoma A₅₄₉DDP Cell Line [J]. PRACTICAL ONCOLOGY JOURNAL, 2009, 23(1): 26-28.

Research progress of CDK4/6 inhibitors combined with endocrine therapy for advanced breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 12

Recommended Articles

Metrics

Comments